Plant-Based Investment Corp.

CNSX:PBIC Stock Report

Market Cap: CA$1.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Plant-Based Investment Valuation

Is PBIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PBIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PBIC (CA$0.05) is trading below our estimate of fair value (CA$0.35)

Significantly Below Fair Value: PBIC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBIC?

Key metric: As PBIC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PBIC. This is calculated by dividing PBIC's market cap by their current book value.
What is PBIC's PB Ratio?
PB Ratio0.1x
BookCA$12.22m
Market CapCA$1.38m

Price to Book Ratio vs Peers

How does PBIC's PB Ratio compare to its peers?

The above table shows the PB ratio for PBIC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.6x
EAST.H EastWest Bioscience
n/an/aCA$2.5m
AGN Algernon Pharmaceuticals
1xn/aCA$2.0m
J Lotus Ventures
0.1xn/aCA$1.2m
CLAS.H Claritas Pharmaceuticals
n/an/aCA$944.7k
PBIC Plant-Based Investment
0.1xn/aCA$1.4m

Price-To-Book vs Peers: PBIC is good value based on its Price-To-Book Ratio (0.1x) compared to the peer average (5.1x).

Price to Book Ratio vs Industry

How does PBIC's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
Industry Avg.1.0x53.4%
PBIC Plant-Based Investment
 0.1xn/aUS$1.02m
BZAM BZAM
0.08xn/aUS$4.88m
CPTR Captor Capital
0.07xn/aUS$1.98m
PBIC 0.1xIndustry Avg. 1.0xNo. of Companies13PB00.61.21.82.43+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.0x53.4%
PBIC Plant-Based Investment
 0.1xn/aUS$1.02m
No more companies

Price-To-Book vs Industry: PBIC is good value based on its Price-To-Book Ratio (0.1x) compared to the Canadian Pharmaceuticals industry average (0.9x)

Price to Book Ratio vs Fair Ratio

What is PBIC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBIC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PBIC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$845.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.39

7D

14.9%

1Y

-59.1%

Fennec Pharmaceuticals

US$109.5m

Operates as a biopharmaceutical company in the United States.

FRX

US$5.68

7D

-3.6%

1Y

-49.7%

Medexus Pharmaceuticals

CA$55.2m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.24

7D

14.3%

1Y

47.4%